IP Verse

Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use Thereof

EP3656860

ALNYLAM PHARMACEUTICALS, INC.
Application Number
EP19192281A
Filing Date
Jun 20, 2012
Status
Granted And Under Opposition
Mar 18, 2022
Grant Date
Apr 20, 2022
External Links
Slate, Register

Biblio Summary

The patent EP3656860B1 was granted on Apr 20, 2022 by Alnylam Pharmaceuticals, Inc. The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GRUNECKER PATENT- UND RECHTSANWALTE PARTG MBBJan 20, 2023ADMISSIBLE

More Opposed Patents of Alnylam Pharmaceuticals, Inc.

The table below shows the patents of Alnylam Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3366775Modified Rnai AgentsApr 27, 20221
EP3105331Ketohexokinase (Khk) Irna Compositions And Methods Of Use ThereofJun 23, 20211
EP2723758Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use ThereofJun 20, 20181

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents